Clinical Trials

Phase 1 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms, Vaccinia

NCT06607185 2026-03-13

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

750 enrolled

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT07216703 2026-03-13

TroFuse-036

Phase 3 Recruiting

1,023 enrolled

Phase 1/2 Not yet recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT07453394 2026-03-06

QLS5132 Combination Therapy in Advanced Solid Tumors

626 enrolled

Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT04221945 2026-02-20

KEYNOTE-A18

1,060 enrolled 30 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT03635567 2026-02-04

KEYNOTE-826

617 enrolled 29 charts 1 FDA

Phase 3 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT04982237 2025-11-19

A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

445 enrolled

Uterine Cervical Neoplasms

NCT07168200 2025-11-17

A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer

Phase 3 Recruiting

720 enrolled

Advanced Cervical Cancer

NCT04956640 2025-09-25

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

Phase 1/2 Recruiting

540 enrolled

Phase 1 Not yet recruiting

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT05570422 2025-09-11

A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01

70 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Uterine Cervical Neoplasms

NCT05007106 2025-08-14

KEYVIBE-005

Phase 2 Completed

613 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT03872947 2025-08-03

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

Phase 1 Active not recruiting

138 enrolled

DermatologicGastrointestinalGenitourinaryGynecologic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT05489211 2025-07-11

Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Phase 2 Recruiting

582 enrolled

GastrointestinalGynecologic

Biliary Tract Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT04634877 2025-06-09

KEYNOTE-B21

Phase 3 Active not recruiting

990 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT06859775 2025-06-06

SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer

Phase 1/2 Recruiting

100 enrolled

EndocrineGynecologicNETThoracic

Uterine Cervical Neoplasms, Recurrence

NCT02489903 2025-03-17

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

Phase 2 Completed

139 enrolled 14 charts

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

NCT04868708 2025-03-04

A Study of AK104（ an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer

Phase 2 Completed

50 enrolled

Phase 2/3 Enrolling by invitation

Diabetes Mellitus, Insulin-Dependent, 12, Uterine Cervical Neoplasms, Recurrence

NCT06755515 2025-01-01

A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer

510 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Uterine Cervical Neoplasms

NCT02009449 2024-11-15

IVY

Phase 1 Completed

353 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT05235516 2024-08-13

AK104-305

Phase 3 Active not recruiting

636 enrolled

Locally Advanced Cervical Carcinoma

NCT03830866 2024-07-26

CALLA

770 enrolled 12 charts

Locally Advanced Cervical Cancer

NCT06241235 2024-04-02

Study of ZG005 in Combination With Paclitaxel＋Platinum-based ± Bevacizumab in Patients With Advanced Cervical Carcinoma

Phase 1/2 Recruiting

48 enrolled

Uterine Cervical Neoplasms

NCT04551950 2024-03-08

Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046)

Phase 1 Completed

25 enrolled 14 charts

Uterine Cervical Neoplasms, Camurati-Engelmann Syndrome

NCT04938583 2023-10-17

Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer

Phase 1/2 Unknown

54 enrolled

Ovarian Neoplasms

NCT01076400 2023-09-18

MK-1775-008

Phase 1/2 Terminated

7 enrolled 6 charts

Uterine Cervical Neoplasms

NCT02855944 2023-06-09

ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients

349 enrolled 29 charts

CNSGenitourinaryGynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence

NCT04851834 2022-12-20

NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma

Phase 1/2 Terminated

12 enrolled

Urinary Bladder Neoplasms, Glioma, Ovarian Neoplasms

NCT05446883 2022-11-30

QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer

Phase 3 Unknown

498 enrolled

Uterine Cervical Neoplasms

NCT04806945 2022-05-05

A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer

Phase 3 Withdrawn

Uterine Cervical Neoplasms

NCT03690739 2022-02-24

Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer

Phase 3 Terminated

9 enrolled

Ovarian Neoplasms

NCT03912415 2020-09-18

FERMATA

Phase 3 Unknown

316 enrolled

Uterine Cervical Neoplasms

NCT01040312 2019-05-23

An Observational Study of CPT-11 Plus Platinum Analogues Regimens and UGT1A1 Genotypes in Solid Tumors

Completed

321 enrolled

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Ovarian Neoplasms, Recurrence, Stomach Neoplasms, Small Cell Lung Carcinoma

NCT03912402 2019-05-09

Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy and Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer (CAESURA)

Phase 2 Unknown

49 enrolled